FR940512-2-00051 FR940512-2-00037 4. Include information on the risks and benefits of alternative strategies for prevention, diagnosis, treatment, and management of the particular health condition(s); and 5. Include information on the costs of alternative strategies for prevention, diagnosis, treatment, and management of the particular health condition(s), where cost information is available and reliable. Section 914 of the Act (42 U.S.C. 299b&hyph;3(a)), as amended by Public Law 102&hyph;410, identifies factors to be considered in establishing priorities for guidelines, including the extent to which the guidelines would: 1. Improve methods for disease prevention; 2. Improve methods of diagnosis, treatment, and clinical management, and thereby benefit a significant number of individuals; 3. Reduce clinically significant variations among clinicians in the particular services and procedures utilized in making diagnoses and providing treatments; and 4. Reduce clinically significant variations in the outcomes of health care services and procedures. Also, in accordance with title IX of the PHS Act and section 1142 of the Social Security Act, the Administrator is to assure that the needs and priorities of the Medicare program are reflected appropriately in the agenda and priorities for development of guidelines. Arrangements for the June 16, 1994 Public Meeting on Update of Cataract in Adults: Management of Functional Impairment Representatives of organizations and other individuals are invited to provide relevant written comments and information, and make a brief (5 minutes or less) oral statement. Individuals and representatives who would like to attend must register with Lynn McQueen, Program Officer, the Office of the Forum for Quality and Effectiveness in Health Care (Forum), at the address set out below by June 1, 1994, and indicate whether they plan to make an oral statement. A written copy of the oral statement should be submitted to the Forum by June 1, 1994. If more requests to make oral statements are received than can be accommodated between 9 a.m. and 12 p.m. on June 16, 1994, time will be allocated in a manner which ensures, to the extent possible, that a range of views of health care professionals, consumers, product manufacturers, and pharmaceutical manufacturers are presented. Those who cannot be granted their requested speaking time because of time constraints are assured that their written comments will be considered when making a decision regarding the update for this guideline. If sign language interpretation or other reasonable accommodation for a disability is needed, please contact the Forum by June 1, 1994, at the address below. Registration should be made with, and written materials submitted to: Ms. Lynn McQueen, Program Officer, Office of the Forum for Quality and Effectiveness in Health Care, Agency for Health Care Policy and Research, Willco Building, 6000 Executive Blvd, suite 310, Rockville, Maryland, 20852, Phone: (301) 594&hyph;4015, Fax: (301) 594&hyph;4027. For Additional Information Additional information on the guideline development process is contained in the AHCPR Program Note, ``Clinical Practice Guideline Development,'' dated August 1993. This document describes AHCPR's activities with respect to clinical practice guidelines including the process and criteria for selecting panels. This document may be obtained from the AHCPR Publications Clearinghouse, P.O. Box 8547, Silver Spring, MD 20907; or call Toll-Free: 1&hyph;800&hyph;358&hyph;9295. Information may also be obtained by contacting Carole Hudgings, Ph.D., Acting Director, Office of the Forum for Quality and Effectiveness in Health Care, Agency for Health Care Policy and Research, Willco Building, 6000 Executive Blvd., Suite 310, Rockville, MD 20852, Phone 301&hyph;594&hyph;4015, Fax: 301&hyph;594&hyph;4027. Dated: May 5, 1994. Linda K. Demlo, Acting Administrator. [FR Doc. 94&hyph;11532 Filed 5&hyph;11&hyph;94; 8:45 am] BILLING CODE 4160&hyph;90&hyph;P
